Tempus AI (TEM) has moved higher on investor interest after launching the ArteraAI Prostate Test for metastatic hormone sensitive prostate cancer and expanding its Bristol Myers Squibb collaboration across cancer and Alzheimer’s clinical trial programs.

Those product and partnership updates come after a mixed stretch for the stock. The 7 day share price return is 5.87%, while the year to date share price return is down 25.95% and the 1 year total shareholder return is down 26.18% from a latest close of US$46.18. This suggests recent momentum has picked up, while longer term performance remains weak.

If you are interested in how other healthcare AI stories are trading, this is a good moment to see which opportunities stand out in the 34 healthcare AI stocks

With revenue at US$1,364.17m, an annual revenue growth rate of 16.43% and ongoing losses of US$302.91m, plus a share price that is down sharply this year, is Tempus AI a potential bargain, or is the market already pricing in future growth?

Most Popular Narrative: 31.3% Undervalued

Analysts following Tempus AI see fair value around $67.20 per share compared with the latest close at $46.18, which frames a sizable valuation gap worth understanding.

Significant volume growth and market share gains in both oncology and hereditary/genetic testing indicate that Tempus AI is leveraging its expanding data repository and technological differentiation to outperform competitors, positioning the company for durable top-line revenue growth.

Read the complete narrative. Read the complete narrative.

Curious what sits behind that valuation gap? The most followed narrative leans heavily on rapid revenue expansion, rising margins and a rich future earnings multiple pinned to 2029 expectations.

Result: Fair Value of $67.20 (UNDERVALUED)

However, there are still clear watchpoints, including reimbursement delays for newer assays as well as tougher genomics and AI competition that could pressure pricing and margins over time.

Another View: Market Pricing Sends A Different Signal

That analyst-led fair value of $67.20 suggests Tempus AI is 31.3% undervalued, but the market is telling a tougher story. The stock trades on a P/S of 6.1x, compared with 3.6x for the wider US Life Sciences industry and 3.1x for peers, and only slightly below its own fair ratio of 6.6x. For you, that mix of discount to fair value and premium to sector benchmarks raises a simple question: is this genuine upside or just higher valuation risk?

Next Steps

The mix of upside potential and clear risk flags makes this a stock where the details really matter. Take a closer look at both sides of the story and weigh them against your own risk tolerance with the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with a single stock. Broaden your watchlist now or you will miss chances that fit your goals and risk comfort.

• Hunt for quality at a discount by checking companies highlighted in the 48 high quality undervalued stocks.
• Build a steadier income stream by reviewing opportunities in the 10 dividend fortresses.
• Focus on resilience first by scanning the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.